Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Indivior Pharmaceuticals Inc. (INDV : NSDQ)

• Company Description    Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. Number of Employees: 1,051

• Price / Volume Information    Yesterday's Closing Price: $32.72 Daily Weekly Monthly 20 Day Moving Average: 1,681,860 shares Shares Outstanding: 125.07 (millions) Market Capitalization: $4,092.14 (millions) Beta: 0.83 52 Week High: $38.00 52 Week Low: $8.34 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.52% -6.71% 12 Week -6.83% -6.95% Year To Date -8.81% -9.25%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10710 Midlothian Turnpike Suite 125 - North Chesterfield,VA 23235 USA ph: 804-379-1040 fax: 804-379-1215 investorrelations@indivior.com http://www.indivior.com

• General Corporate Information    Officers Mark Crossley - Chief Executive Officer David Wheadon - Chairman Ryan Preblick - Chief Financial Officer Woodrow Anderson - Senior Vice President Juliet Thompson - Director Peer Information Indivior Pharmaceuticals Inc. (GSAC) Indivior Pharmaceuticals Inc. (CASIF) Indivior Pharmaceuticals Inc. (ALCD.) Indivior Pharmaceuticals Inc. (OMNN) Indivior Pharmaceuticals Inc. (CGPI.) Indivior Pharmaceuticals Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 45579U109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 04/23/26 Share - Related Items Shares Outstanding: 125.07 Most Recent Split Date: (:1) Beta: 0.83 Market Capitalization: $4,092.14 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.63 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $3.01 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 04/23/26

• Fundamental Ratios P/E Current FY Estimate: 10.88 Trailing 12 Months: 13.30 PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: 12.03 Price / Sales: 3.30 EPS Growth vs. Year Ago Period: 156.25% vs. Previous Quarter: 13.89% Sales Growth vs. Year Ago Period: 20.13% vs. Previous Quarter: 14.01% ROE 12/31/25 - -148.76 09/30/25 - -91.71 06/30/25 - -87.19 ROA 12/31/25 - 23.15 09/30/25 - 17.92 06/30/25 - 16.26 Current Ratio 12/31/25 - 0.71 09/30/25 - 0.96 06/30/25 - 0.90 Quick Ratio 12/31/25 - 0.55 09/30/25 - 0.79 06/30/25 - 0.76 Operating Margin 12/31/25 - 25.40 09/30/25 - 21.10 06/30/25 - 19.44 Net Margin 12/31/25 - 16.85 09/30/25 - 9.83 06/30/25 - 6.65 Pre-Tax Margin 12/31/25 - 19.29 09/30/25 - 16.61 06/30/25 - 16.11 Book Value 12/31/25 - -0.78 09/30/25 - - 06/30/25 - - Inventory Turnover 12/31/25 - 1.59 09/30/25 - 1.43 06/30/25 - 1.28 Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Capital 12/31/25 - - 09/30/25 - - 06/30/25 - -

Powered by Zacks Investment Research ©